RESUMEN
Microglial activation results in profound morphological, functional and gene expression changes that affect the pro- and anti-inflammatory mechanisms of these cells. Although statins have beneficial effects on inflammation, they have not been thoroughly investigated for their ability to affect microglial functions. Therefore the effects of rosuvastatin, one of the most commonly prescribed drugs in cardiovascular therapy, either alone or in combination with bacterial lipopolysaccharide (LPS), were profiled in pure microglial cultures derived from the forebrains of 18-day-old rat embryos. To reveal the effects of rosuvastatin on a number of pro- and anti-inflammatory mechanisms, we performed morphometric, functional and gene expression studies relating to cell adhesion and proliferation, phagocytosis, pro- and anti-inflammatory cytokine (IL-1ß, tumor necrosis factor α (TNF-α) and IL-10, respectively) production, and the expression of various inflammation-related genes, including those related to the above morphological parameters and cellular functions. We found that microglia could be an important therapeutic target of rosuvastatin. In unchallenged (control) microglia, rosuvastatin inhibited proliferation and cell adhesion, but promoted microspike formation and elevated the expression of certain anti-inflammatory genes (Cxcl1, Ccl5, Mbl2), while phagocytosis or pro- and anti-inflammatory cytokine production were unaffected. Moreover, rosuvastatin markedly inhibited microglial activation in LPS-challenged cells by affecting both their morphology and functions as it inhibited LPS-elicited phagocytosis and inhibited pro-inflammatory cytokine (IL-1ß, TNF-α) production, concomitantly increasing the level of IL-10, an anti-inflammatory cytokine. Finally, rosuvastatin beneficially and differentially affected the expression of a number of inflammation-related genes in LPS-challenged cells by inhibiting numerous pro-inflammatory and stimulating several anti-inflammatory genes. Since the microglia could elicit pro-inflammatory responses leading to neurodegeneration, it is important to attenuate such mechanisms and promote anti-inflammatory properties, and develop prophylactic therapies. By beneficially regulating both pro- and anti-inflammatory microglial functions, rosuvastatin may be considered as a prophylactic agent in the prevention of inflammation-related neurological disorders.
Asunto(s)
Antiinflamatorios/farmacología , Inflamación/metabolismo , Inflamación/fisiopatología , Microglía/efectos de los fármacos , Microglía/metabolismo , Rosuvastatina Cálcica/farmacología , Animales , Adhesión Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Células Cultivadas , Citocinas/metabolismo , Expresión Génica/efectos de los fármacos , Inflamación/inducido químicamente , Inflamación/genética , Mediadores de Inflamación/metabolismo , Lipopolisacáridos , Microglía/citología , Microglía/fisiología , Fagocitosis/efectos de los fármacos , Prosencéfalo/citología , Ratas , Ratas Sprague-DawleyRESUMEN
Combination therapy of bortezomib with other chemotherapeutics is an emerging treatment strategy. Since both curcumin and bortezomib inhibit NF-κB, we tested the effects of their combination on leukemia cells. To improve potency, a novel Mannich-type curcumin derivative, C-150, was synthesized. Curcumin and its analogue showed potent antiproliferative and apoptotic effects on the human leukemia cell line, HL60, with different potency but similar additive properties with bortezomib. Additive antiproliferative effects were correlated well with LPS-induced NF-κB inhibition results. Gene expression data on cell cycle and apoptosis related genes, obtained by high-throughput QPCR, showed that curcumin and its analogue act through similar signaling pathways. In correlation with in vitro results similar additive effect could be obsereved in SCID mice inoculated systemically with HL60 cells. C-150 in a liposomal formulation given intravenously in combination with bortezomib was more efficient than either of the drugs alone. As our novel curcumin analogue exerted anticancer effects in leukemic cells at submicromolar concentration in vitro and at 3 mg/kg dose in vivo, which was potentiated by bortezomib, it holds a great promise as a future therapeutic agent in the treatment of leukemia alone or in combination.
Asunto(s)
Apoptosis/efectos de los fármacos , Bortezomib/farmacología , Curcumina/farmacología , Leucemia/tratamiento farmacológico , Leucemia/metabolismo , Animales , Curcumina/análogos & derivados , Células HL-60 , Humanos , Leucemia/patología , Ratones , Ratones SCID , Ensayos Antitumor por Modelo de XenoinjertoAsunto(s)
Regulación de la Expresión Génica/genética , Genes MHC Clase II/genética , Hipnosis , Linfocitos/metabolismo , Regulación hacia Arriba/genética , Ligando 4-1BB/genética , Ciclooxigenasa 2/genética , Citocinas/genética , Factor de Crecimiento Epidérmico/genética , Factor de Crecimiento de Hepatocito/genética , Humanos , Masculino , Psiconeuroinmunología , Factor de Necrosis Tumoral alfa/genéticaRESUMEN
Thyroid nodules are common. It would very helpful if genetic markers that can diagnose malignancy from fine needle aspiration samples were available. Few such markers has been thus identified and none are specific. Large panels of potential markers can be screened by microarray technology. Studies done to date have concentrated on single tumor types and thus provide no help in identifying tumor subtype specific markers. To that end we have studied gene profiles of 5 types of benign and malignant thyroid nodular tissue (multinodular goiter, follicular adenoma, papillary and follicular carcinomas). We have identified 195 genes whose differential expression clustered into clinically relevant groups. Twenty-eight genes were selected for further confirmation using real time quantitative polymerase chain reaction. Despite the differences in the microarray panels used, we confirmed the differential regulation of 12 genes previously reported in thyroid cancer, although we found the expression of several genes to be regulated in other histological tumor subtypes than originally described. We found, PCSK2, TRIB1, RAP1 GA1 to be specifically overexpressed in follicular cancer and S100A4 and GK2 in papillary carcinoma. SERP1, RNASE 2 and STATA5 were suppressed in papillary thyroid cancer. We have thus identified new potential markers specific to malignant thyroid tumors. It is apparent that a range of nodular thyroid tissue using large tumor sample numbers is necessary to establish robust markers for malignancy and to categorize tumors on the basis of small tumor samples.
Asunto(s)
Perfilación de la Expresión Génica , Genes Relacionados con las Neoplasias , Neoplasias de la Tiroides/diagnóstico , Neoplasias de la Tiroides/genética , Adenocarcinoma Folicular/diagnóstico , Adenocarcinoma Folicular/genética , Adenocarcinoma Folicular/fisiopatología , Adenoma/diagnóstico , Adenoma/genética , Adenoma/fisiopatología , Biomarcadores de Tumor/genética , Biopsia con Aguja Fina , Carcinoma Papilar/diagnóstico , Carcinoma Papilar/genética , Carcinoma Papilar/fisiopatología , Regulación Neoplásica de la Expresión Génica , Bocio Nodular/diagnóstico , Bocio Nodular/genética , Bocio Nodular/fisiopatología , Humanos , Microscopía Confocal , Análisis de Secuencia por Matrices de Oligonucleótidos , Reacción en Cadena de la Polimerasa , Neoplasias de la Tiroides/fisiopatologíaRESUMEN
In DNA microarray technology, repeatability and reliability are very important to compare multiple RNA samplesfrom different experiments. The application of common or universal RNA as a standard control equalizes the differences in hybridization parameters and array variations. For this purpose, high-quality reference RNA is necessary in bulk amounts. A novel approach was developed to get milligrams of sense or antisense RNA, starting from micrograms of pooled total RNA from different cell lines, tissues, or organisms. This method is inexpensive and allows further labeling procedures using poly(dT) or random oligomers as primers. In addition, amplified, sense reference RNA is suitable for standard labeling protocols, while the antisense reference RNA can be used with antisense RNA from the linear sample amplification method. Here we produced universal RNA for human, rat, and alfalfa and demonstrated the quality using specific cDNA microarrays.
Asunto(s)
Análisis de Secuencia por Matrices de Oligonucleótidos/métodos , ARN/aislamiento & purificación , Animales , Secuencia de Bases , Humanos , Hibridación de Ácido Nucleico , Reacción en Cadena de la Polimerasa , RatasRESUMEN
Galanin-like peptide (GALP) was recently isolated from the hypothalamus, where its expression is influenced by leptin and food deprivation. Since leptin crosses the blood-brain barrier (BBB) by a saturable transport system that is downregulated by fasting, we examined the effect of leptin and fasting on the entry of GALP into mouse brain. Multiple-time regression analysis showed that the basal influx of 125I-GALP from blood was rapid (K(i) = 9.49 +/- 0.72 x 10(-4) ml/g x min). This influx was not affected by leptin but was significantly decreased by food deprivation for 24 or 48 h, accompanied by decreased immunoreactive plasma GALP at 48 h, but not at 24 h. By contrast, pretreatment of mice fasted for 24 h with glucose resulted in a significant increase in the blood-to-brain influx of GALP that was not accompanied by increased immunoreactive plasma GALP. HPLC showed that most of the GALP crossed the BBB in an intact form, and capillary depletion studies showed that more than 93% of the GALP crossing entered the parenchyma of the brain rather than being bound to the endothelial cells of the capillaries composing the BBB or being reversibly associated with the vasculature. Efflux of 125I-GALP occurred at the rate of the normal reabsorption of CSF, and the octanol-buffer partition coefficient showed insufficient lipophilicity to explain the fast rate of influx. When 125I-GALP was perfused in blood-free buffer, the self-inhibition characteristic of a saturable transport system was evident even though capillary gel electrophoresis showed GALP aggregating as a trimer. Capillary zone electrophoresis showed protein binding of GALP in serum, perhaps facilitating its interactions at the BBB. In particular, these studies show for the first time (1) that immunoreactive GALP is present in blood where (2) its concentrations are reduced by food deprivation, and (3) that there is a rapid blood-to-brain influx of intact GALP (4) which is decreased by fasting and (5) increased by pretreatment with glucose.
Asunto(s)
Encéfalo/metabolismo , Privación de Alimentos/fisiología , Proteínas del Tejido Nervioso/farmacocinética , Animales , Barrera Hematoencefálica , Tampones (Química) , Capilares/metabolismo , Cromatografía , Cromatografía Líquida de Alta Presión , Relación Dosis-Respuesta a Droga , Electroforesis , Péptido Similar a Galanina , Glucosa/farmacología , Inyecciones Intravenosas , Masculino , Ratones , Ratones Endogámicos ICR , Proteínas del Tejido Nervioso/administración & dosificación , Proteínas del Tejido Nervioso/sangre , Perfusión , RadioinmunoensayoRESUMEN
Adrenomedullin (ADM) is present both in the periphery and brain. In addition to its peripheral effects, this peptide can exert central effects such as decreasing food ingestion. We used multiple-time regression analysis to determine that labeled ADM can cross from blood to brain with an apparent influx constant (K(I)) of 5.83 +/- 1.44 x 10(-4) ml/g-min, much faster than that of albumin, the vascular control. HPLC showed that almost all of the injected 125I-ADM in the brain was intact, and capillary depletion showed that it could reach the parenchyma of the brain. However, more 125I-ADM was reversibly associated with the brain vasculature than we have seen with any other peptide tested by these methods. After intracerebroventricular injection, 125I-ADM exited the brain with the bulk reabsorption of cerebrospinal fluid at an efflux rate comparable to that of albumin. Although there was no blood-to-brain saturation, in situ brain perfusion of 125I-ADM in blood-free physiological buffer showed self-inhibition by excess unlabeled ADM. This, along with evidence of the lack of protein binding shown by capillary zone electrophoresis, indicated competition for the binding site of ADM at the BBB. The low lipophilicity of ADM determined by the octanol/buffer partition coefficient was also consistent with the prominent reversible association of ADM with the vasculature of the BBB. This suggests a function for ADM at the cerebral blood vessels, such as altering cerebral blood flow and perfusion, without disruption of the BBB.
Asunto(s)
Barrera Hematoencefálica/fisiología , Péptidos/farmacocinética , Adrenomedulina , Animales , Tampones (Química) , Capilares/fisiología , Circulación Cerebrovascular/fisiología , Fenómenos Químicos , Química Física , Cromatografía Líquida de Alta Presión , Electroforesis Capilar , Inyecciones Intraventriculares , Radioisótopos de Yodo , Leptina/metabolismo , Masculino , Ratones , Ratones Endogámicos ICR , Nitroglicerina/farmacología , Péptidos/sangre , Análisis de Regresión , Vasodilatadores/farmacologíaRESUMEN
Agouti-related protein (AgRP), expressed in both the periphery and the brain, can result in obesity. Its active C-terminal fragment, AgRP(83-132), was recently reported to increase feeding and antagonize alpha-melanocyte-stimulating hormone (alpha-MSH) and leptin. We used multiple-time regression analysis to show that the rate at which AgRP(83-132) crossed the blood-brain barrier (BBB) from the blood to the brain was very slow (Ki = 0.6 x 10(-4) mL/g x min). Entry was not self-inhibited by excess AgRP(83-132) after either intravenous (i.v.) injection or perfusion in blood-free medium, indicating the absence of a saturable transport system, and was not cross-inhibited by alpha-MSH or leptin. Not only did AgRP(83-132) cross much slower than the saturably entering leptin, but the entry was slower than almost all other non-saturably entering endogenous peptides or neurotrophins. Nevertheless, high-performance liquid chromatography (HPLC) showed that the small amount of AgRP(83-132) crossing the BBB did so in intact form, and capillary depletion showed that it entered the brain parenchyma rather than binding to capillary endothelial cells or adhering to vascular components. There was no rapid efflux system out of the brain that might have misleadingly appeared as slow entry for AgRP(83-132). Poor lipophilicity was shown by a low octanol/buffer partition coefficient. By size-exclusion chromatography, AgRP(83-132) appeared as a 17-kd substance in both blood and buffer. Since protein was absent from the buffer, the 17-kd peak probably represented a trimer of the 5.7-kd AgRP(83-132). Capillary electrophoresis confirmed that most of the AgRP(83-132) existed as a trimer, with much smaller amounts as a dimer and monomer. Thus, although intact AgRP(83-132) can cross the BBB from the blood to the brain, its nonsaturable rate of entry is very slow, probably influenced by aggregation.
Asunto(s)
Barrera Hematoencefálica , Fragmentos de Péptidos/farmacocinética , Proteína Relacionada con Agouti , Animales , Encéfalo/metabolismo , Cromatografía en Gel , Cromatografía Líquida de Alta Presión , Electroforesis Capilar , Semivida , Masculino , Ratones , Ratones Endogámicos ICRRESUMEN
Melanin-concentrating hormone (MCH), found both peripherally and centrally, is involved in food ingestion. Although its expression in brain is increased by fasting, it is not known whether it crosses the blood-brain barrier (BBB). Use of the sensitive method of multiple-time regression analysis has shown that almost all of the peptides and polypeptides tested cross the BBB at a rate faster than the vascular marker albumin. With this same method, however, we found that the 19-amino acid 125I-Phe13,Tyr19-MCH did not cross faster than 99mTc-albumin. Several mechanisms were excluded as possible explanations for the slow rate of influx. These included degradation, association with capillary endothelial cells, and transport from brain to blood. When Phe13,Tyr19-MCH was perfused in blood-free buffer, however, it entered the brain significantly faster than albumin. This suggested protein binding as an explanation for the slow rate of influx when the MCH was administered in blood. Protein binding was confirmed by capillary zone electrophoresis, which showed that almost all of the Phe13,Tyr19-MCH added to blood migrated with a large-molecular-weight substance. Sodium dodecyl sulfate-capillary gel electrophoresis of Phe13,Tyr19-MCH in buffer additionally showed that the MCH aggregated as a trimer, a factor not preventing its influx by blood-free perfusion. Thus, the results show that blood-borne Phe13,Tyr19-MCH does not significantly cross the BBB, probably because of its binding to serum proteins.
Asunto(s)
Barrera Hematoencefálica , Hormonas Hipotalámicas/farmacocinética , Melaninas/farmacocinética , Hormonas Hipofisarias/farmacocinética , Animales , Proteínas Sanguíneas/metabolismo , Encéfalo/irrigación sanguínea , Encéfalo/metabolismo , Capilares/metabolismo , Cromatografía Líquida de Alta Presión , Electroforesis Capilar , Inyecciones Intravenosas , Inyecciones Intraventriculares , Masculino , Ratones , Ratones Endogámicos ICR , Perfusión , Albúmina Sérica/farmacocinéticaRESUMEN
Endomorphin-1 (Tyr-Pro-Trp-Phe-NH2, EM-1) and endomorphin-2 (Tyr-Pro-Phe-Phe-NH2, EM-2) are peptides recently isolated from brain that show the highest affinity and selectivity for the mu (morphine) opiate receptor of all the known endogenous opioids. The endomorphins have potent analgesic and gastrointestinal effects. At the cellular level, they activate G-proteins (35S-GTP gamma-S binding) and inhibit calcium currents. Support for their role as endogenous ligands for the mu-opiate receptor includes their localization by radioimmunoassay and immunocytochemistry in central nervous system regions of high mu receptor density. Intense EM-2 immunoreactivity is present in the terminal regions of primary afferent neurons in the dorsal horn of the spinal cord and in the medulla near high densities of mu receptors. Chemical (capsaicin) and surgical (rhizotomy) disruption of nociceptive primary afferent neurons depletes the immunoreactivity, implicating the primary afferents as the source of EM-2. Thus, EM-2 is well-positioned to serve as an endogenous modulator of pain in its earliest stages of perception. In contrast to EM-2, which is more prevalent in the spinal cord and lower brainstem, EM-1 is more widely and densely distributed throughout the brain than EM-2. The distribution is consistent with a role for the peptides in the modulation of diverse functions, including autonomic, neuroendocrine, and reward functions as well as modulation of responses to pain and stress.
Asunto(s)
Bulbo Raquídeo/fisiología , Neuronas/fisiología , Oligopéptidos/fisiología , Receptores Opioides mu/fisiología , Médula Espinal/fisiología , Vías Aferentes/fisiología , Animales , Humanos , Receptores Opioides mu/agonistasRESUMEN
The endogenous opioid peptides, endomorphin 1 and 2, are newly isolated, potent, and selective mu-opioid receptor agonists. In the present study, responses to endomorphin 1 and 2 were investigated in the systemic vascular bed of the rat. Endomorphin 1 and 2 induced dose-related decreases in systemic arterial pressure when injected in doses of 1-30 nmol/kg i.v. In terms of relative vasodepressor activity, endomorphin 1 and 2 were approximately equipotent with each other and with the ORL1 ligand, nociceptin (orphanin FQ), and were about 10-fold more potent than met-enkephalin in decreasing systemic arterial pressure. Vasodepressor responses to endomorphin 1 and 2 and met-enkephalin, but not to nociceptin, were inhibited by the opioid receptor antagonist, naloxone. These results demonstrate that endomorphin 1 and 2 produce significant naloxone-sensitive decreases in systemic arterial pressure.
Asunto(s)
Analgésicos Opioides/farmacología , Presión Sanguínea/efectos de los fármacos , Oligopéptidos/farmacología , Receptores Opioides mu/agonistas , Vasoconstrictores/farmacología , Analgésicos Opioides/farmacocinética , Animales , Encefalina Metionina/farmacología , Femenino , Masculino , Oligopéptidos/farmacocinética , Péptidos Opioides/farmacología , Ratas , Ratas Sprague-Dawley , Vasoconstrictores/farmacocinética , NociceptinaRESUMEN
The endogenous peptides endomorphins 1 and 2 are newly isolated, potent, and selective mu-opioid receptor agonists. In the present study, responses to the endomorphin peptides were investigated in the systemic vascular bed of the rabbit. Endomorphins 1 and 2 induced dose-related decreases in systemic arterial pressure when injected in doses of 1-30 nmol/kg i.v. In terms of relative vasodepressor activity, endomorphins 1 and 2 were similar to the ORL1 receptor ligand, nociceptin (Orphanin FQ), and met-enkephalin in decreasing systemic arterial pressure. Vasodepressor responses to endomorphins 1 and 2 were inhibited by the opioid receptor antagonist, naloxone, in a dose of 2 mg/kg i.v. These results demonstrate that endomorphins 1 and 2 have significant naloxone-sensitive, vasodepressor activity in the rabbit.
Asunto(s)
Analgésicos Opioides/farmacología , Presión Sanguínea/efectos de los fármacos , Oligopéptidos/farmacología , Receptores Opioides mu/agonistas , Animales , Antihipertensivos , Relación Dosis-Respuesta a Droga , Encefalina Metionina/farmacología , Femenino , Masculino , Naloxona/farmacología , Péptidos Opioides/farmacología , Conejos , NociceptinaRESUMEN
Peptides have been identified in mammalian brain that are considered to be endogenous agonists for the delta (enkephalins) and kappa (dynorphins) opiate receptors, but none has been found to have any preference for the mu receptor. Because morphine and other compounds that are clinically useful and open to abuse act primarily at the mu receptor, it could be important to identify endogenous peptides specific for this site. Here we report the discovery and isolation from brain of such a peptide, endomorphin-1 (Tyr-Pro-Trp-Phe-NH2), which has a high affinity (Ki = 360 pM) and selectivity (4,000- and 15,000-fold preference over the delta and kappa receptors) for the mu receptor. This peptide is more effective than the mu-selective analogue DAMGO in vitro and it produces potent and prolonged analgesia in mice. A second peptide, endomorphin-2 (Tyr-Pro-Phe-Phe-NH2), which differs by one amino acid, was also isolated. The new peptides have the highest specificity and affinity for the mu receptor of any endogenous substance so far described and they may be natural ligands for this receptor.
Asunto(s)
Analgésicos Opioides/aislamiento & purificación , Endorfinas/aislamiento & purificación , Oligopéptidos/aislamiento & purificación , Receptores Opioides mu/agonistas , Secuencia de Aminoácidos , Analgésicos Opioides/metabolismo , Analgésicos Opioides/farmacología , Animales , Química Encefálica , Bovinos , Endorfinas/metabolismo , Endorfinas/fisiología , Encefalina Ala(2)-MeFe(4)-Gli(5) , Encefalinas/metabolismo , Hormona Inhibidora de la Liberación de MSH/análogos & derivados , Hormona Inhibidora de la Liberación de MSH/química , Hormona Inhibidora de la Liberación de MSH/metabolismo , Ratones , Oligopéptidos/fisiología , RadioinmunoensayoRESUMEN
Endomorphin 1 and 2 are recently discovered endogenous ligands for the mu-opioid receptor. In the present study, responses to intravenous administration of endomorphin 1 and 2 were investigated in the systemic vascular bed of the rat. Endomorphin 1 and 2 induced dose-related decreases in systemic arterial pressure when injected in doses of 10-100 nmol/kg i.v.. The decreases in systemic arterial pressure in response to endomorphin 1 and 2 were associated with significant decreases in heart rate, cardiac output, and total peripheral resistance. The endogenous ligand for the ORL1 receptor, nociceptin/OFQ had similar effects on systemic arterial pressure, heart rate, cardiac output, and total peripheral resistance in the rat. Injections of isoproterenol (1 microgram/kg i.v.) and calcitonin gene-related peptide (CGRP; 0.3 nmol/kg i.v.), decreased systemic arterial pressure and total peripheral resistance. However these decreases in arterial pressure were associated with increases in heart rate and cardiac output. The results of the present study demonstrate that the endomorphin peptides have significant vasodilator activity in the systemic vascular bed of the rat and show that this response is associated with a decrease in heart rate and cardiac output.
Asunto(s)
Gasto Cardíaco/efectos de los fármacos , Oligopéptidos/farmacología , Receptores Opioides mu/agonistas , Resistencia Vascular/efectos de los fármacos , Animales , Péptido Relacionado con Gen de Calcitonina/farmacología , Cardiotónicos/farmacología , Femenino , Isoproterenol/farmacología , Ligandos , Masculino , Péptidos Opioides/farmacología , Ratas , Ratas Sprague-Dawley , NociceptinaRESUMEN
Endomorphin-1 (Tyr-Pro-Trp-Phe-NH2) and endomorphin-2 (Tyr-Pro-Phe-Phe-NH2) were previously isolated from bovine brain. Both peptides showed the greatest selectivity and affinity for the mu opiate receptor of any endogenous substance found to date and may serve as natural ligands for the mu-opiate receptor. We have purified them from the fronto-parietal cortex of human brain tissue by solid phase extraction and high performance liquid chromatography. Peptide content was followed by a specific and sensitive radioimmunoassay with an antibody that was generated against endomorphin-1. The isolated endomorphins showed full biological activity. The tetrapeptides were found in human brain in much higher amounts than in bovine frontal cortex.
Asunto(s)
Corteza Cerebral/química , Oligopéptidos/aislamiento & purificación , Secuencia de Aminoácidos , Analgésicos Opioides/aislamiento & purificación , Animales , Unión Competitiva , Bovinos , Cromatografía Líquida de Alta Presión , Encefalina Ala(2)-MeFe(4)-Gli(5) , Encefalinas/metabolismo , Humanos , Oligopéptidos/síntesis química , Oligopéptidos/química , Oligopéptidos/metabolismo , Radioinmunoensayo , Receptores Opioides mu/agonistas , Receptores Opioides mu/metabolismoRESUMEN
Aminosteroids were prepared and acylated with protected amino acids by means of the mixed anhydride or the active ester method. The tert-butyloxycarbonyl- (BOC) protecting group was eliminated by acidolysis, and the benzyloxycarbonyl- (Z) group by catalytic hydrogenation. 3 beta- and 6 beta-Glycylamidosteroids were prepared by indirect amination of chloroacetamido derivatives, formed by the Ritter reaction on the corresponding 3 alpha,5 alpha-cyclo and 5 alpha,6 alpha-epoxy steroids. Water-soluble double salts were produced from the compounds for pharmacological investigations.
Asunto(s)
Aminoácidos/química , Esteroides/síntesis química , Androstanos/química , Pregnanos/química , Pregnatrienos/química , Solubilidad , Esteroides/químicaRESUMEN
Two endogenous brain peptides (Tyr-W-MIF-1 (Tyr-Pro-Trp-Gly-NH2) and Tyr-MIF-1 (Tyr-Pro-Leu-Gly-NH2)), a cyclized analog and two fragments of Tyr-W-MIF-1, and hemorphin (Tyr-Pro-Trp-Thr) were tested for binding to mu 1 and mu 2 opiate receptor. All these peptides bound to both mu 1 and mu 2 sites in assays optimized to discriminate these subtypes of the mu opiate receptor in membranes from bovine thalamus. The cyclized analog of Tyr-W-MIF-1, previously shown to have potency near that of Tyr-D-Ala-Gly-N-MePhe-Gly-ol (DAMGO) and morphine in producing analgesia after intracerebroventricular (i.c.v.) injection, bound to mu 1 and mu 2 sites with affinities similar to those of DAMGO. Tyr-W-MIF-1, previously shown to induce analgesia after i.c.v. injection but with much higher potency after intrathecal (i.t.) injection, also bound to both mu 1 and mu 2 sites with an affinity between that of morphiceptin and hemorphin. Although the highest ratios of Ki's for mu 2/mu 1 were shown by hemorphin, Tyr-W-MIF-1, and Tyr-W-MIF-1, none of the compounds were significantly different in selectivity. The results indicate that the relatively lower potency of Tyr-W-MIF-1 after i.c.v., compared with i.t. injection, is not due to a lack of binding to mu 1 sites. They suggest that it has relatively high efficacy at mu 2, but low efficacy at mu 1 sites, a possibility that might explain some of the novel properties of these peptides.
Asunto(s)
Unión Competitiva , Hormona Inhibidora de la Liberación de MSH/análogos & derivados , Antagonistas de Narcóticos/farmacología , Péptidos/farmacología , Receptores Opioides mu/efectos de los fármacos , Tálamo/efectos de los fármacos , Animales , Bovinos , Relación Dosis-Respuesta a Droga , Hormona Inhibidora de la Liberación de MSH/farmacologíaRESUMEN
Two samples of the peptide tyrosine-melanocyte-stimulating hormone release-inhibiting factor-1 (Tyr-MIF-1; Tyr-Pro-Leu-Gly-NH2) were tritiated on different amino acids (Tyr or Pro) and incubated together at 37 degrees C with fractions of rat brain. The amount of intact tetrapeptide remaining was determined by HPLC. By 3 min, most of the Tyr-MIF-1 was degraded. Because similar amounts of [3H]Pro and [3H]Tyr appeared after incubation of the Tyr-MIF-1 peptides in brain homogenate, even as early as 30 s, examination of only this crude preparation would misleadingly indicate that Tyr-MIF-1 is not a precursor of melanocyte-stimulating hormone release-inhibiting factor-1 (MIF-1; Pro-Leu-Gly-NH2) in brain tissue. However, incubation of the mitochondrial fractions of brain under the same conditions resulted in more than three times as much [3H]Tyr being formed as [3H]Pro, with accompanying accumulation of MIF-1. Addition of excess MIF-1 to the mitochondrial fraction completely suppressed the formation of MIF-1 and more than doubled the amount of Tyr-MIF-1 remaining intact. When Tyr-MIF-1 tritiated only on the Tyr was added to the mitochondrial fraction, the main peaks of radioactivity appeared only at the positions of Tyr and Tyr-MIF-1, not at the position of Tyr-Pro. The results indicate that Tyr-MIF-1 can serve as a precursor of MIF-1 in brain mitochondria, an effect not evident when crude brain homogenate is used.
Asunto(s)
Encéfalo/metabolismo , Hormona Inhibidora de la Liberación de MSH/análogos & derivados , Hormona Inhibidora de la Liberación de MSH/biosíntesis , Mitocondrias/metabolismo , Animales , Cromatografía Líquida de Alta Presión , Hormona Inhibidora de la Liberación de MSH/metabolismo , Masculino , Ratas , Ratas Sprague-DawleyRESUMEN
Tyr-MIF-1-like immunoreactivity (Tyr-MIF-1-LI) was measured in the plasma of hypophysectomized rats. The concentrations were increased in every rat examined, regardless of sex or time after hypophysectomy, and ranged from 2.5 to 10 times greater than the concentrations in intact rats. The elevated concentrations were not decreased by replacement by thyroxine, estrogen and progesterone, or acute injection of corticosterone. Chronic administration of physiological doses of corticosterone, however, did reduce the concentrations to normal. High performance liquid chromatography of tritiated Tyr-MIF-1 incubated at 37 degrees C for 3 min in plasma obtained by hypophysectomized rats eliminated the possibility that reduced degradation of Tyr-MIF-1 explained the increased concentrations. Thus, the increase in Tyr-MIF-1-LI in the plasma of hypophysectomized rats is robust and reversible by chronic replacement of corticosterone.
Asunto(s)
Corticosterona/farmacología , Hormona Inhibidora de la Liberación de MSH/análogos & derivados , Animales , Femenino , Hipofisectomía , Inmunohistoquímica , Hormona Inhibidora de la Liberación de MSH/sangre , Hormona Inhibidora de la Liberación de MSH/farmacología , Masculino , Hipófisis/fisiología , Ratas , Factores de TiempoRESUMEN
Tyr-MIF-1 previously was isolated from tissue obtained after death. A possible role of autolysis could not be excluded. We report the isolation of Tyr-MIF-1 (Tyr-Pro-Leu-Gly-NH2) in increased amounts from fresh human brain cortex. This confirms the natural existence of this brain peptide.